CAR-T Meeting 2023 | Incorporating patient perspectives in CAR-T therapy: trial design, access to therapies, QoL & more
Solène Clavreul, PhD, Myeloma Patients Europe, Brussels, Belgium, shares some insights into a session that took place at the 5th European CAR T-cell Meeting, which focused on incorporating patient perspectives in CAR-T therapy. Dr Clavreul gives an overview of the topics that were addressed in this session, including clinical trial access and design, challenges faced by patients, quality of life (QoL) measurements, and communication between patients and clinicians. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
No personal disclosures. MPE receives funding from: AstraZenca, Amgen, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Mundipharma, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Takeda, Gilead, Sebia, Prothena, SkylineDx, Sandoz
